金融界9月17日消息，新锐医药公布，其在此期间的总收益约为16,718,000港元，较截至2023年6月30日止六个月的约31,016,000港元减少约46.1%。收入下降主要是由于中国大陆在多个地区进一步加强抗菌药物分级及分类管理政策带来的不利影响，导致期内对该类产品的需求减少。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.